• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Asthma, biologics, corticosteroids, and coronavirus disease 2019.

作者信息

Akenroye Ayobami T, Wood Robert, Keet Corinne

机构信息

Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

出版信息

Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.

DOI:10.1016/j.anai.2020.05.001
PMID:32387535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7202805/
Abstract
摘要

相似文献

1
Asthma, biologics, corticosteroids, and coronavirus disease 2019.哮喘、生物制剂、皮质类固醇与2019冠状病毒病
Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.
2
Common concerns in managing bronchial asthma during the COVID-19 pandemic.在新冠疫情期间管理支气管哮喘的常见问题。
Int J Tuberc Lung Dis. 2020 Jul 1;24(7):750-752. doi: 10.5588/ijtld.20.0378.
3
Assessment and management of adults with asthma during the covid-19 pandemic.2019冠状病毒病大流行期间成人哮喘的评估与管理
BMJ. 2020 Jun 8;369:m2092. doi: 10.1136/bmj.m2092.
4
Anaphylactic shock following the diagnosis of coronavirus disease 2019.2019冠状病毒病诊断后发生的过敏性休克。
Ann Allergy Asthma Immunol. 2020 Oct;125(4):477-478. doi: 10.1016/j.anai.2020.07.032. Epub 2020 Aug 1.
5
COVID-19 in a patient with severe asthma treated with Omalizumab.使用奥马珠单抗治疗的重度哮喘患者中的新型冠状病毒肺炎
Allergy. 2020 Oct;75(10):2705-2708. doi: 10.1111/all.14456. Epub 2020 Jun 27.
6
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.初步数据表明，皮肤科使用的生物制剂与新冠肺炎不良结局无关。
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
7
Successful treatment of coronavirus disease 2019 in a patient with asthma.一名哮喘患者的新型冠状病毒肺炎成功治疗案例。
Allergy Asthma Proc. 2020 Jul 1;41(4):296-300. doi: 10.2500/aap.2020.41.200044.
8
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
9
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
10
[Drugs that aggravate the course of COVID-19 : really ?].[加重新型冠状病毒肺炎病程的药物：真的吗？]
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):852-854.

引用本文的文献

1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".新冠病毒感染使用奈玛特韦-利托那韦（帕罗韦德）治疗后寻求医疗护理的风险因素：“症状反弹”
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
A retrospective study regarding the influence of COVID-19 disease on asthma.一项关于 COVID-19 疾病对哮喘影响的回顾性研究。
BMC Pulm Med. 2023 Jan 17;23(1):22. doi: 10.1186/s12890-023-02309-7.
3
Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.识别与 COVID-19 患者住院死亡率相关的预先存在的疾病和多种合并症模式。
Sci Rep. 2022 Oct 15;12(1):17313. doi: 10.1038/s41598-022-20176-w.
4
Understanding and Managing Severe Asthma in the Context of COVID-19.在2019冠状病毒病背景下理解和管理重度哮喘
Immunotargets Ther. 2021 Dec 11;10:419-430. doi: 10.2147/ITT.S342636. eCollection 2021.
5
The effects of the antecedent use of inhaled steroid on the clinical course of COVID-19: A retrospective study of asthmatic patients.吸入性类固醇药物在 COVID-19 临床病程中的作用：哮喘患者的回顾性研究。
J Infect Public Health. 2022 Jan;15(1):56-64. doi: 10.1016/j.jiph.2021.12.003. Epub 2021 Dec 8.
6
The evidence is in that asthma is not associated with severe coronavirus disease 2019.有证据表明，哮喘与严重的2019冠状病毒病无关。
Ann Allergy Asthma Immunol. 2021 May;126(5):451-452. doi: 10.1016/j.anai.2021.02.023.
7
Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis.哮喘与 COVID-19 感染、住院、入住 ICU 和死亡风险：系统评价和荟萃分析。
J Asthma. 2022 May;59(5):866-879. doi: 10.1080/02770903.2021.1888116. Epub 2021 Apr 1.
8
Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview.在冠状病毒病（COVID-19）大流行期间的肥胖、营养不良和微量元素缺乏：概述。
Nutrition. 2021 Jan;81:111016. doi: 10.1016/j.nut.2020.111016. Epub 2020 Sep 8.
9
Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases.气道中 ACE2 的表达：对慢性炎症性呼吸道疾病患者 COVID-19 风险和疾病管理的影响。
Clin Exp Allergy. 2020 Dec;50(12):1313-1324. doi: 10.1111/cea.13746. Epub 2020 Oct 6.
10
Authors' response.作者回复。
Ann Allergy Asthma Immunol. 2020 Sep;125(3):362. doi: 10.1016/j.anai.2020.06.018.

本文引用的文献

1
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.2020 年 3 月 1 日至 30 日，14 个州住院的经实验室确诊的 2019 冠状病毒病患者的住院率和特征 - COVID-NET。
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
2
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.患者康复前伴随免疫反应的广度：非重症COVID-19病例报告
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
3
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.COVID-19：过敏与免疫学门诊的大流行应急规划。
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5. doi: 10.1016/j.jaip.2020.03.012. Epub 2020 Mar 26.
4
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
5
MERS, SARS and other coronaviruses as causes of pneumonia.中东呼吸综合征冠状病毒、严重急性呼吸综合征冠状病毒等冠状病毒引起的肺炎。
Respirology. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20.
6
Viral infections and asthma: an inflammatory interface?病毒感染与哮喘：炎症的相互作用？
Eur Respir J. 2014 Dec;44(6):1666-81. doi: 10.1183/09031936.00047714. Epub 2014 Sep 18.
7
Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children.变应性哮喘儿童的高亲和力 IgE 受体降低了对鼻病毒的固有免疫反应。
J Allergy Clin Immunol. 2012 Aug;130(2):489-95. doi: 10.1016/j.jaci.2012.05.023. Epub 2012 Jul 4.
8
Role of viral respiratory infections in asthma and asthma exacerbations.病毒呼吸道感染在哮喘和哮喘恶化中的作用。
Lancet. 2010 Sep 4;376(9743):826-34. doi: 10.1016/S0140-6736(10)61380-3.
9
Asthma as a risk factor for invasive pneumococcal disease.哮喘作为侵袭性肺炎球菌疾病的一个风险因素。
N Engl J Med. 2005 May 19;352(20):2082-90. doi: 10.1056/NEJMoa044113.
10
Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection.上、下呼吸道细胞因子与实验性鼻病毒感染结果的关系。
Am J Respir Crit Care Med. 2000 Dec;162(6):2226-31. doi: 10.1164/ajrccm.162.6.2003019.